Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
59.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc
Capital Expenditures
Ultragenyx Pharmaceutical Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
Capital Expenditures
-$20.9m
|
CAGR 3-Years
35%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-28%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$888m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$974m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$508.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$928.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
Ultragenyx Pharmaceutical Inc
Glance View
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The company is headquartered in Novato, California and currently employs 1,119 full-time employees. The company went IPO on 2014-01-31. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
See Also
What is Ultragenyx Pharmaceutical Inc's Capital Expenditures?
Capital Expenditures
-20.9m
USD
Based on the financial report for Sep 30, 2024, Ultragenyx Pharmaceutical Inc's Capital Expenditures amounts to -20.9m USD.
What is Ultragenyx Pharmaceutical Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-28%
Over the last year, the Capital Expenditures growth was 71%. The average annual Capital Expenditures growth rates for Ultragenyx Pharmaceutical Inc have been 35% over the past three years , -8% over the past five years , and -28% over the past ten years .
You don't have any saved screeners yet
